"Ezetimibe" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.
| Descriptor ID |
D000069438
|
| MeSH Number(s) |
D03.383.082.301.550
|
| Concept/Terms |
Ezetimibe- Ezetimibe
- (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone)
- Ezetimib
SCH 58235- SCH 58235
- 58235, SCH
- SCH-58235
- SCH58235
|
Below are MeSH descriptors whose meaning is more general than "Ezetimibe".
Below are MeSH descriptors whose meaning is more specific than "Ezetimibe".
This graph shows the total number of publications written about "Ezetimibe" by people in this website by year, and whether "Ezetimibe" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 2 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 6 | 6 | 12 |
| 2018 | 5 | 7 | 12 |
| 2019 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Ezetimibe" by people in Profiles.
-
Identification of drugs associated with reduced severity of COVID-19 - a case-control study in a large population. Elife. 2021 07 27; 10.
-
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.
-
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020 04; 27(6):593-603.
-
Bempedoic acid and ezetimibe - better together. Eur J Prev Cardiol. 2020 04; 27(6):590-592.
-
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. J Clin Lipidol. 2019 Jul - Aug; 13(4):586-593.e5.
-
Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
-
What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? Curr Vasc Pharmacol. 2019; 17(5):425-428.
-
Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy. J Cardiovasc Med (Hagerstown). 2018 Sep; 19(9):485-490.
-
Call for an ezetimibe effectiveness test. Atherosclerosis. 2018 11; 278:334.
-
Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec; 18(6):655-666.